ST. LOUIS (May 13, 2013) – RiverVest Venture Partners announced today that Bradley Keller, Ph.D. has joined the life sciences venture capital firm as an Entrepreneur-in-Residence.
Keller brings with him more than 20 years of experience in drug discovery and development, including scientific leadership roles at Pfizer, Pharmacia, Monsanto/Searle and Hoffman-LaRoche, and most recently, as Global Product Manager with Sigma-Aldrich. As a 2009-10 Innovation Acceleration Partnership Fellow at Washington University in St. Louis, Keller participated in a National Science Foundation training program in entrepreneurship and commercialization of science and technology.
In addition to his position as a RiverVest Entrepreneur-in-Residence, Keller serves as V.P., Research at Lumena Pharmaceuticals, Inc. in San Diego, CA, a role which currently requires most of his time. Lumena is a RiverVest portfolio company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically improve patient health.
As Entrepreneur-in-Residence, Keller will work with the RiverVest team to identify and evaluate potential funding opportunities in the pharmaceutical and biotechnology space. “We are excited to have Brad on the team,” says John McKearn, RiverVest Managing Director. “He has the perfect set of skills and experience to help us, particularly as we selectively found promising life science companies with the intention of building and selling them within five years.”
Keller has a Ph.D. in Biochemistry from the University of Kansas and a B.A. in Biology and Chemistry from the University of Delaware. He also completed post-doctoral studies in Pharmaceutical Chemistry at the University of Kansas.